Day: March 22, 2024

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2023 full-year financial results on Thursday, March 28, 2024. Inventiva’s 2023 full-year financial results will be published on Wednesday, March 27, 2024 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, and Jean Volatier, Chief Financial...

Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development work Today’s update on Day 67 and Day 90 event rates is the first of two planned public updates on symptomatic COVID-19 events in CANOPY; Invivyd plans to analyze all future events at Day 180 Further defining the relationship between serum virus neutralizing antibody titers and clinical protection that prospectively builds on published data is an anticipated goal of future clinical trialsWALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced interim exploratory COVID-19 clinical event data...

FORT WORTH, Texas, March 22, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 147,500 shares of common stock at a purchase price of $8.00 per share. In a concurrent private placement, the Company also issued unregistered warrants to purchase up to 147,500 shares of common stock at an exercise price of $8.00 per share which are immediately exercisable for a period of five and one-half years following the date of issuance. H.C. Wainwright & Co....

NEXLETOL® (bempedoic acid) Tablet– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes Data and Reflect a Highly Differentiated Product Profile – – Positive CHMP Opinion Received; European Cardiovascular (CV) Risk Reduction Label Determination Anticipated in Q2 2024 – – Conference Call and Webcast on Monday, March 25 at 8:00 a.m. ET – ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications...

Figure 1. Calculated sVNA titers against JN.1 based on observed pharmacokinetic concentration by timepoints (Cohort A)Figure 1PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency use authorization based on positive immunobridging data and on safety data from the CANOPY clinical trial along with ongoing in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1 PEMGARDA is the first PrEP monoclonal antibody (mAb) to receive EUA from the U.S. FDA based on a novel, rapid, repeatable immunobridging trial design PEMGARDA is the first authorized mAb from Invivyd’s novel technology platform approach designed to address the challenge of rapid viral evolution Product availability in the U.S. anticipated imminently Estimated...

Montrouge, 22 March 2024 Crédit Agricole S.A. informs the public that the French version of its 2023 Universal Registration Document and Annual Financial Report have been filed with the French Financial Market Authority (AMF) on March 22nd, 2024, under number D.24-0156. The following documents are included in the Registration Document:the 2023 Annual Financial Report; the report on corporate governance; the informations on fees paid to the statutory auditors.The French version of the document is available on the Crédit Agricole S.A. website https://www.credit-agricole.com/finance/publications-financieres , as well as on the website of AMF. A reproduction translated in English is also available on the website of Crédit Agricole S.A.https://www.credit-agricole.com/en/finance/financial-publications Press contacts of Crédit Agricole...

LAS VEGAS, Nevada, March 22, 2024 (GLOBE NEWSWIRE) —  Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $50.0 million securitization of residual interests from previously issued securitizations. In the transaction, a qualified institutional buyer purchased $50.0 million of asset-backed notes secured by an 80% interest in a CPS affiliate that owns the residual interests in five CPS securitizations issued from January 2022 through January 2023. Collateral for the notes includes 80% of the amounts on deposit in the underlying spread accounts for each related securitization and 80% of the over-collateralization of each related securitization, which is the difference between the outstanding principal balance of the related receivables less the outstanding principal balance of...

Release of the English version of the Universal registration document and Annual financial report 2023 Press release Paris, 22 March 2024 BNP Paribas announces the publication of the English version of the Universal registration document and Annual financial report 2023. The Universal registration document and Annual financial report 2023 was filed with the Autorité des Marchés Financiers (AMF) on 22 March 2024 and is listed under n° D.24-0158. It includes : • the Annual financial report 2023 ; • the corporate governance report; and • Information on the fees of statutory auditors. The document is available on BNP Paribas website at the following address https://invest.bnpparibas/en/search/reports/documents/financial-reports and on the AMF website.AttachmentRelease of the English version of the Universal registration...